BrightHeart Obtains Second FDA Clearance for Expansion of Platform Capabilities - Adding Tablet Support For Fetal Heart Ultrasound Evaluations

Written By Amanda French

PARIS--(BUSINESS WIRE)-- BrightHeart, a global leader in artificial intelligence (AI) solutions for obstetrics and pediatric cardiology, announced today the 510(k) clearance for updates to the BrightHeart platform, which adds the capability for clinicians to access the BrightHeart analysis in real-time through a cart-side tablet.

Continue reading the full press release here.

Amanda French
Previous

BrightHeart Obtains Third FDA Clearance and PCCP Approval, Becoming First to Offer One Integrated Solution for Real-Time Fetal Heart Documentation and CHD Detection
Next

BrightHeart’s AI demonstrates promise in congenital heart defect detection